ArticleBiological psychiatry2012
Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions.
Article in Biological psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Disruptive resting state networks characterizing depressive comorbidity in Alzheimer's disease and mild cognitive impairment.Journal of Alzheimer's disease : JAD · 2025Pooled it
- Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns.Molecular neurodegeneration · 2021Pooled it
- A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.Journal of Alzheimer's disease : JAD · 2017Pooled it
- Positive affect disrupts neurodegeneration effects on cognitive training plasticity in older adults.Social cognitive and affective neuroscience · 2024Trial
- Feasibility and Effect Sizes of the Revised Daily Engagement of Meaningful Activities Intervention for Individuals With Mild Cognitive Impairment and Their Caregivers.Journal of gerontological nursing · 2016Trial
- Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.Journal of Alzheimer's disease : JAD · 2016Trial
- Age-dependent alterations of TRPA1 and urocortin 1 signaling in the Edinger-Westphal nucleus in a mouse model of Alzheimer's disease.Scientific reports · 2026Article
- Bidirectional prognostic predictions of conversion and reversion in amnestic mild cognitive impairment.GeroScience · 2026Article
- White Matter Hyperintensities and Neuropsychiatric Symptoms in Neurodegenerative Diseases.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Development and validation of a risk prediction model for mild cognitive impairment in older Chinese adults with chronic diseases.BMC geriatrics · 2026Observational
- Association between higher cerebrospinal fluid levels of phosphorylated tau and reduced depressive symptoms in patients with cognitive decline.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Protective Potential ofCurrent issues in molecular biology · 2025Review
- Anxious-depressive symptoms and sleep disturbances across the Alzheimer disease spectrum.Nature. Mental health · 2025Article
- Persistent depressive symptom trajectory is associated with cognitive impairment: a population-based longitudinal study of aging in Taiwan.BMC geriatrics · 2025Article
- Plasma neurofilament light chain mediates the effect of subsyndromal symptomatic depression on cognitive decline in older adults.Frontiers in aging neuroscience · 2025Article
- Self- and study partner-reported cognitive decline in older adults without dementia: The role of α-synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- From Mild Cognitive Impairment to Dementia: The Impact of Comorbid Conditions on Disease Conversion.Biomedicines · 2024Article
- Article
- The neural basis of neuropsychiatric symptoms in Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
backgroundDepression has been associated with higher conversion rates from mild cognitive impairment (MCI) to Alzheimer's disease (AD) and may be a marker of prodromal AD that can be used to identify individuals with MCI who are most likely to progress to AD. Thus, we examined the neuroanatomical changes associated with depressive symptoms in MCI.
methodsTwo-hundred forty-three MCI subjects from the Alzheimer's Disease Neuroimaging Initiative who had brain magnetic resonance imaging scans at baseline and 2-year follow-up were classified into depressed (n = 44), nondepressed with other neuropsychiatric symptoms (n = 93), and no-symptom (NOSYMP; n = 106) groups based on the Neuropsychiatric Inventory Questionnaire. Tensor-based morphometry was used to create individual three-dimensional maps of 2-year brain changes that were compared between groups.
resultsDepressed subjects had more frontal (p = .024), parietal (p = .030), and temporal (p = .038) white matter atrophy than NOSYMP subjects. Those whose depressive symptoms persisted over 2 years also had higher conversion to AD and more decline on measures of global cognition, language, and executive functioning compared with stable NOSYMP subjects. Nondepressed with other neuropsychiatric symptoms and NOSYMP groups exhibited no differences in rates of atrophy.
conclusionsDepressive symptoms were associated with greater atrophy in AD-affected regions, increased cognitive decline, and higher rates of conversion to AD. Depression in individuals with MCI may be associated with underlying neuropathological changes, including prodromal AD, and may be a potentially useful clinical marker in identifying MCI patients who are most likely to progress to AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.